Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies
New severity grading and targeted treatments for a rare immune condition called hemophagocytic lymphohistiocytosis are improving recognition and management.
This review from New York Medical College proposes a novel CTCAE v5.0-based grading system for HLH incorporating key prognostic factors, addressing the longstanding absence of standardized HLH severity assessment. New targeted therapies (emapalumab, ruxolitinib, tocilizumab) and emerging options (IL-18 inhibitors, TNFα inhibitors) are summarized.
What the study was
- Study design
- Narrative review with proposed grading system
- Population
- HLH patients (primary and secondary)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Clinical Advances in Hematology and Oncology
Why it surfaced
Novel HLH grading classification addresses clinical gap; targeted therapies directly relevant to hematologic malignancy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.